ReviewCureus2026
Safety and Effectiveness of Bupropion for Smoking Cessation During Pregnancy: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking during pregnancy is associated with adverse maternal, fetal, and neonatal outcomes. Although behavioral counseling remains first-line treatment, pharmacotherapy may be considered when counseling alone is insufficient. This scoping review mapped the available evidence on the safety and effectiveness of bupropion for smoking cessation during pregnancy. The review was conducted according to Joanna Briggs Institute methodology and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). MEDLINE (PubMed), Embase, the Cochrane Library, PsycINFO, and ClinicalTrials.gov were searched without date restrictions for English-language studies evaluating bupropion for smoking cessation during pregnancy. Two reviewers independently screened records, and the review team extracted data on smoking cessation, maternal safety, and fetal or neonatal outcomes. Of 599 records identified, 13 sources of evidence met the inclusion criteria. Maternal and fetal safety findings were generally reassuring, with no consistent increase in maternal adverse events, major congenital malformations, preterm birth, impaired fetal growth, or serious neonatal morbidity. Evidence for smoking cessation effectiveness was mixed. Some studies reported improved short-term abstinence, reduced cigarette consumption or tobacco exposure, and improvement in craving or withdrawal symptoms, whereas other randomized trials found no significant improvement in sustained abstinence compared with placebo or counseling. Interpretation was limited by small samples, few bupropion-exposed pregnancies, heterogeneous designs and outcomes, and restrictive trial eligibility criteria. Current evidence is more reassuring regarding maternal, fetal, and neonatal safety than it is conclusive regarding smoking cessation effectiveness. Larger, adequately powered studies involving more representative pregnant populations are needed to clarify efficacy and detect uncommon adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.